Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000045432 | SCV000073445 | likely benign | Hereditary breast ovarian cancer syndrome | 2025-01-17 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000583191 | SCV000689100 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-09-18 | criteria provided, single submitter | clinical testing | This missense variant replaces isoleucine with threonine at codon 2718 of the BRCA2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in 14 individuals affected with breast cancer, however, it is described as a polymorphism and the status of covariants was not provided (PMID: 20859677, 23096355). This variant has been identified in 2/251248 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
Counsyl | RCV000031722 | SCV000786481 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 2 | 2018-05-08 | criteria provided, single submitter | clinical testing | |
Mendelics | RCV000031722 | SCV001139207 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 2 | 2019-05-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000583191 | SCV001189752 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-05-30 | criteria provided, single submitter | clinical testing | The p.I2718T variant (also known as c.8153T>C), located in coding exon 17 of the BRCA2 gene, results from a T to C substitution at nucleotide position 8153. The isoleucine at codon 2718 is replaced by threonine, an amino acid with similar properties. This alteration has been identified in multiple individuals diagnosed with breast cancer (Lara K et al. Biol. Res. 2012;45:117-30; Alvarez C et al. Oncotarget, 2017 Sep;8:74233-74243). Of note, this alteration is also known as 8381T>C in published literature. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |
Gene |
RCV002305440 | SCV002599649 | uncertain significance | not provided | 2022-11-01 | criteria provided, single submitter | clinical testing | Observed in individuals with breast cancer (Gonzalez-Hormazabal et al., 2011; Lara K et al., 2012; Alvarez et al., 2017); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Also known as 8381T>C; This variant is associated with the following publications: (PMID: 29088781, 19043619, 23096355, 20859677, 12228710, 32377563, 29884841) |
All of Us Research Program, |
RCV004803076 | SCV005425788 | uncertain significance | BRCA2-related cancer predisposition | 2024-03-24 | criteria provided, single submitter | clinical testing | This missense variant replaces isoleucine with threonine at codon 2718 of the BRCA2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in 14 individuals affected with breast cancer, however, it is described as a polymorphism and the status of covariants was not provided (PMID: 20859677, 23096355). This variant has been identified in 2/251248 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
Sharing Clinical Reports Project |
RCV000031722 | SCV000054329 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 2 | 2010-05-12 | no assertion criteria provided | clinical testing | |
Breast Cancer Information Core |
RCV000031722 | SCV000147283 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 2 | 2003-12-23 | no assertion criteria provided | clinical testing | |
BRCAlab, |
RCV000031722 | SCV004243804 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 2 | 2020-03-02 | no assertion criteria provided | clinical testing |